Albus Health Expands Global Footprint with Availability across Latin America, Asia-Pacific and Middle East, Enabling Standardised Data Collection in Multinational Clinical Trials

• Albus Health has expanded its fully passive, clinical‑grade nocturnal monitoring platform to 40+ countries, giving pharma a globally deployable solution for consistent, regulator‑ready real‑world data.
• The company’s contactless Albus Home system reduces patient burden while delivering high‑fidelity sleep, cough, vital‑sign and environmental data that strengthens evidence packages for multinational trials.
• With established regulatory and operational pathways worldwide, Albus enables pharma to scale beyond pilots and run large, multi‑country studies with greater consistency, lower friction and richer patient‑centred insights.

Oxford, UK; May 20, 2026. Albus Health, a leader in multimodal nocturnal health monitoring, has expanded its operational footprint beyond Europe and North America, and is now supporting pharmaceutical clinical research in more than 40 countries. The company’s innovative platform, Albus Home, measures sleep, vital signs, symptoms including cough, and air quality. These parameters are monitored with clinical-grade accuracy, without patients needing to do or wear anything.

The expansion significantly enhances the company’s ability to deliver passive, clinical‑grade, real‑world data at the scale required for today’s global clinical development programmes. Pharmaceutical sponsors are increasingly seeking technologies that provide standardised, regulator‑ready evidence across geographies, including in high priority regions such as China. Albus’ expanded presence allows global trials to run with greater consistency, reduced operational friction and richer insight into real-world evidence, while minimising patient burden and broadening participant diversity.

Albus is currently enabling high-quality data collection in global studies by multiple top 10 pharma across North America, Latin America, Asia-Pacific and Middle East, with end-to-end logistics and data lifecycle management support. In addition, the company is advancing certifications in several high‑priority markets, strengthening its capacity to support multinational programmes from R&D through to commercial and marketing.

A Scalable Platform Designed to Avoid “Death by Pilot”

In these regions, Albus and its pharmaceutical partners have established the regulatory, logistical and data management pathways needed to run large, multi‑country studies, enabling sponsors to collect consistent, GCP-compliant real‑world data from patients’ homes at global scale.

This reach allows pharma companies to move beyond the industry’s common “death by pilot” trap and design trials that can expand from a single‑country pilot to broad international roll out on a single platform.

“Scaling beyond clinical pilots is one of the biggest challenges that pharma companies face with novel technologies,” said Mikesh Udani, Co‑Founder & CEO, Albus Health. “When we founded the company, our mission was to collect data reliably from any patient, anywhere, and for as long as needed. Having demonstrated high patient acceptability across patient populations, global certifications and pathways were the last piece of the puzzle to achieve operational scale.”

Albus matches clinical gold-standard accuracy and sustains high compliance data collection across multi-year studies. To deploy the Albus Home in sites across the globe, the company provides an end-to-end service from study setup and site support to closeout. The Oxford-based company delivers directly to the trial sites, taking the operational complexity away from the sponsor.

Sleep as a Burgeoning Sector for Pharma

Sleep is rapidly emerging as a critical frontier in understanding human health, with patients becoming increasingly aware of the impact sleep has on quality of life. Mounting evidence shows that sleep patterns, nocturnal symptoms and overnight physiology can objectively measure disease burden, quality of life and long-term outcomes in patients across a range of therapeutic areas. Across respiratory, rare disease, oncology, metabolic and GLP‑1‑related programmes, pharma’s shift toward patient‑centred outcomes is elevating sleep as a key marker of therapeutic value.

“Sleep is a powerful lens into overall health,” Udani added. “But disruption to sleep due to symptoms has a different meaning to a patient waking up simply to have a sip of water. Measuring sleep along with cough, vital signs and environmental factors such as air quality can provide more colour and completeness to the data, helping reveal the true impact of the drug while removing any confounders.”

Standardised global data collection provides trial sponsors with a coherent evidence package that reduces regional discrepancies, strengthens comparability of outcomes, and supports faster, more aligned regulatory submissions across markets.

To speak with a member of the Albus Health team, please email: hello@albushealth.com.

About Albus Health

Albus Health is an Oxford-spinout health technology company pioneering fully contactless, bedside monitoring systems that capture continuous nocturnal health data. Its flagship product, Albus Home, uses a combination of advanced sensors and AI algorithms to monitor cough, vital signs, sleep parameters, and environmental factors, enabling high‑quality data collection for clinical trials, real‑world evidence programmes, and long‑term disease management.

Albus Health partners with leading pharmaceutical companies, academic institutions and patient advocacy groups to advance research and improve outcomes for people living with chronic and rare conditions.

Learn more at: www.albushealth.com